Novavax Q2 revenue falls 76% to $57 million and swings to $53 million net loss
Novavax reported second quarter 2026 total revenue of $57 million, down 76% from $239 million a year earlier, when results included $202 million from a Nuvaxovid approval milestone and a Takeda amendment. The company posted a net loss of $53 million, or $0.32 per share, compared with net income of $107 million a year earlier. It raised its full-year 2026 adjusted revenue framework and lowered its combined R&D and SG&A expense guidance, so shareholders face a sharp revenue decline alongside higher revenue guidance and lower expense guidance.
Key points
- Q2 2026 total revenue was $57 million vs $239 million in Q2 2025; Sanofi revenue fell to $36 million from $199 million
- Net loss of $53 million ($0.32 per share) vs net income of $107 million in Q2 2025 (basic EPS $0.66)
- Full-year 2026 Adjusted Total Revenue framework raised to $235 million-$275 million from $230 million-$270 million
- Combined R&D and SG&A expense guidance lowered to $370 million-$410 million from $380 million-$420 million; cash was $724 million at June 30, 2026
The filing
Written by AI on Nov 9, 2026, 8:29 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on August 06, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.